GlassScriptPhysician profile
Jonathan P Hilts
NPI 1093061988
$1,822.92
in general payments reported to CMS, 2019-2025
34 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $71.62 · 2022: $243 · 2023: $204 · 2024: $640 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.89 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $510.43 | 2023-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $160.58 | 2019-2024 | Ultomiris, Strensiq |
| Actelion Pharmaceuticals US, INC. | $123.25 | 2019-2022 | |
| Biogen, INC. | $87.42 | 2024-2025 | Vumerity |
| Aurinia Pharma U.S., INC. | $83.65 | 2024 | Lupkynis |
| Abbvie INC. | $76.03 | 2019-2025 | |
| Amgen INC. | $69.95 | 2024-2025 | Krystexxa |
| Grifols USA, LLC | $61.28 | 2019-2020 | |
| Horizon Therapeutics Plc | $60.43 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.17 | 2019-2020 | |
| Ucb, INC. | $41.10 | 2023-2025 | Bimzelx, Cimzia |
| Boston Scientific Corporation | $38.67 | 2024 | |
| Lilly USA, LLC | $34.92 | 2022-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.11 | 2022-2023 | Ofev |
| Eisai INC. | $31.41 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $30.17 | 2019 | |
| Sandoz INC. | $28.54 | 2025 | Hyrimoz |
| Pfizer INC. | $27.94 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $23.00 | 2022 | |
| Abbott Laboratories | $21.94 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.94 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $20.20 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $20.16 | 2025 | |
| Merz North America, INC. | $18.69 | 2019 | |
| Glaxosmithkline, LLC. | $18.68 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.42 | 2019 | |
| Neurocrine Biosciences, INC. | $17.81 | 2023 | Ongentys, Ingrezza |
| Tanabe Pharma America, INC. | $17.49 | 2024 | |
| Kyowa Kirin, INC. | $16.95 | 2023 | Crysvita |
| Amylyx Pharmaceuticals, INC. | $14.79 | 2023 | Relyvrio |
| United Therapeutics Corporation | $14.38 | 2024 | Tyvaso |
| Radius Health, INC. | $13.66 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $12.63 | 2020 | |
| Genentech USA, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hilts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.